“…The uncertainty results from two sets of observations: animal experiments that have been interpreted as suggesting a protective role for oxLDL antibodies (13) and conflicting data obtained in clinical and epidemiological studies that tried to correlate levels of oxLDL antibodies in serum with different end points of arteriosclerosis. These discrepancies are likely to result from multiple factors, including individual variations in the immune response, affecting concentration, isotype, and avidity of the autoantibodies, and inaccuracy of the assays, highly influenced by differences in antibody avidity and by the presence of soluble IC.…”